| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-08-29 | BioInvent (Sweden) undisclosed major global pharmaceutical company | undisclosed product | production manufacturing |
Technology - Services | Production agreement | |
| 2016-08-29 | Saniona (Denmark) Boehringer Ingelheim (Germany) | novel compounds for the treatment of schizophrenia | schizophrenia | collaboration |
CNS diseases - Mental diseases | Collaboration agreement |
| 2016-08-26 | Orchard Therapeutics (UK) | nomination | Rare diseases - Genetic diseases | Nomination | ||
| 2016-08-25 | Recipharm (Sweden) | construction of new premises |
Technology - Services | Construction of new premises | ||
| 2016-08-25 | Valneva (France- Austria) Seqirus (UK) | Sandovac®, Fluad® | influenza | distribution marketing |
Infectious diseases | Distribution agreement |
| 2016-08-25 | Denali Therapeutics (USA - CA) F-star (UK) | multispecific antibody platform to deliver therapeutics across the blood-brain barrier | collaboration development |
CNS diseases | Collaboration agreement | |
| 2016-08-25 | BioLineRx (Israel) I-Bridge Capital (China) iPharma (China) | joint venture agreement |
Cardiovascular diseases - Metabolic diseases - Respiratory diseases | Joint-venture agreement | ||
| 2016-08-25 | BiolineRx (Israel) I-Bridge Capital (China) | iPharma | joint-venture |
Joint-venture agreement | ||
| 2016-08-24 | Txcell (France) | nomination |
Autoimmune diseases – Inflammatory diseases | Nomination | ||
| 2016-08-24 | Neurovive Pharmaceutical (Sweden) | resignation |
Resignation | |||
| 2016-08-24 | Merck&Co (USA - NJ) Biothera Pharmaceuticals (USA - MN) | Imprime PGG and Keytruda® (pembrolizumab) | clinical research collaboration |
Cancer - Oncology | Clinical research agreement | |
| 2016-08-24 | Lion Biotechnologies (USA - CA) National Cancer Institute (NCI) (USA) | combination of tumor-infiltrating lymphocytes (TIL) with FDA-approved drugs, such as checkpoint inhibitors | melanoma, bladder cancer, lung cancer, triple-negative breast cancer, HPV-associated cancers (including cervical and head and neck cancers) | development |
Cancer - Oncology | Development agreement |
| 2016-08-23 | Jacobs Engineering Group (USA - CA) Pfizer (USA - NY) | Pfizer Global Biotechnology Center in China | services contract
construction of new premises |
Technology - Services | Construction of new premises | |
| 2016-08-23 | Gilead Sciences (USA - CA) | nomination |
Nomination | |||
| 2016-08-22 | Scancell (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-08-22 | DS Biopharma (Ireland) Afimmune (Ireland) | DS102, DS107 | atopic dermatitis, pruritus, NASH (non-alcoholic steatohepatitis), chronic obstructive pulmonary disease (COPD), Idiopathic pulmonary fibrosis (IPF) | establishment of a new subsidiary in the EU |
Dermatologic diseases - Fibrotic diseases - Liver diseases - Hepatic diseases - Lung diseases - Rare diseases - Respiratory diseases | Establishment of a new subsidiary in the EU |
| 2016-08-22 | Regeneron Pharmaceuticals (USA - NY) Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) (USA) | antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS) | Middle East Respiratory Syndrome (MERS) | collaboration |
Infectious diseases | Collaboration agreement |
| 2016-08-22 | Y-mAbs Therapeutics (USA - NY) Abzena (UK) | bispecific 3F8-antibody | production manufacturing |
Cancer - Oncology | Production agreement | |
| 2016-08-22 | XBiotech (USA - TX) | opening of new premises | Opening of new premises | |||
| 2016-08-19 | Bayer (Germany) CRISPR Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) | blood disorders, blindness, congenital heart diseases | joint-venture agreement |
Rare diseases - Genetic diseases - Hematological diseases - Ophtalmological diseases - Cardiovascular disease | Establishment of a new subsidiary in the US |
